Figure 1: Phy sicochemical characterization of Sor-NPs in terms of A) sizedistribution, B) zeta potential, and C) morphology, (TEM, original magnification 66.000x). D) Representative HPLC-MS/MS chromatograms for sorafenib: (I) a blank sample (PLGA particle), (II) a calibrator sample spiked with 0.5 μg/mL sorafenib (III) a Sor-NPs sample 4 days after the start of the release study.